

Amendment

R.J. Reynolds Tobacco Company

Camel Snus Briefing Materials

9 References (Amended)

No.	Citation	Title
1	Accortt et al. 2005	Accortt NA, Waterbor JW, Beall C, and Howard G. 2005. Cancer incidence among a cohort of smokeless tobacco users (United States). <i>Cancer Causes Control</i> 16:1107-1115.
2	Arias 2010	Arias E. 2010. United States life tables, 2006. National Vital Statistics Reports, Vol. 58, No. 21, June 28, 2010. Hyattsville, MD: National Center for Health Statistics. (Accessed September 20, 2016 at https://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf)
3	Bachand and Sulsky 2013	Bachand AM and Sulsky SI. 2013. A dynamic population model for estimating all-cause mortality due to lifetime exposure history. <i>Regulatory Toxicology and Pharmacology</i> 67:246-251.
4	Bachand et al. 2018	Bachand A, Sulsky S, and Curtin G. 2018. Assessing the Likelihood and Magnitude of a Population Health Benefit Following the Market Introduction of a Modified-Risk Tobacco Product: Enhancements to the Dynamic Population Modeler, DPM(+1). <i>Risk Analysis</i> , Vol. 38, No. 1.
5	Blank and Eissenberg 2010	Blank MD and Eissenberg T. 2010. Evaluating oral noncombustible potential-reduced exposure products for smokers. <i>Nicotine Tob Res</i> 12(4):336-43.
6	Blot et al. 1988	Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, and Fraumeni JF. 1988. Smoking and drinking in relation to oral and pharyngeal cancer. <i>Cancer Res</i> 48:3282-3287.
7	Boffetta et al. 2005	Boffetta P, Aagnes B, Weiderpass E, and Andersen A. 2005. Smokeless tobacco use and risk of cancer of the pancreas and other organs. <i>Int J Cancer</i> 114:992-995.
8	Boffetta et al. 2008	Boffetta P, Hecht S, Gray N, Gupta P, and Straif K. 2008. Smokeless tobacco and cancer. <i>Lancet Oncol.</i> 9, 667-675.
9	Borgerding et al. 2012	Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. 2012. The chemical composition of smokeless tobacco: A survey of products sold in the United States in 2006 and 2007. <i>Regul Toxicol Pharmacol.</i> Dec; 64(3):367-387.
10	Borgida et al. 2015	Borgida E, Loken B, Williams AL, Vitriol JV, Stepanov I, and Hatsukami D. 2015. Assessing constituent levels in smokeless tobacco products: A new approach to engaging and educating the public. <i>Nic & Tob Res</i> 99(00),1-8.
11	Brown et al. 1988	Brown LM, Blot WJ, Schuman SH, et al. 1988. Environmental Factors and High Risk of Esophageal Cancer Among Men in Coastal South Carolina, <i>J Natl Cancer Inst</i> 80(20):1620-1625.
12	Burris et al. 2014	Burris JL, Carpenter MJ, Wahlquist AE, Cummings KM, and Gray KM. 2014. Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit: a pilot randomized clinical trial. <i>Nicotine & Tob Res</i> 16(4):397-405.
13	Burris et al. 2016	Burris JL, Wahlquist AE, Alberg AJ, Cummings KM, Gray KM, Garrett-Mayer E, Carpenter MJ. 2016. A longitudinal, naturalistic study of U.S. smokers' trial and adoption of snus. <i>Addict Behav.</i> Dec; 63:82-8.
14	Byrne et al. 2012	Byrne S, Guillory JE, Mathios AD, Avery RJ, Hart PS. 2012. The unintended consequences of disclosure: Effect of manipulating sponsor identification on the perceived credibility and effectiveness of smoking cessation advertisements. <i>J Health Commun</i> 17(10):1119-1137.

No.	Citation	Title
15	Caraway and Chen 2013	Caraway JW, Chen PX. 2013. Assessment of mouth-level exposure to tobacco constituents in U.S. snus consumers. <i>Nicotine Tob Res.</i> Mar;15(3):670-677.
16	Carman et al. 2010	Carman KL, Mauer M, Yegian JM, Dardess P, McGee J, Evers M, and Marlo KO. 2010. Evidence that consumers are skeptical about evidence-based health care. <i>Health Affairs.</i> 29(7):1400-1406. (Accessed June 13, 2016 at http://content.healthaffairs.org/content/early/2010/06/03/hlthaff.2009.0296.full.pdf+html)
17	Carpenter et al. 2016	Carpenter MJ, Wahlquist AE, Burris JL, Gray KM, Garrett-Mayer E, Cummings KM, Alberg AJ. 2016. Snus undermines quit attempts but not abstinence: a randomized clinical trial among US smokers. <i>Tob Control</i> Apr 12. pii: tobaccocontrol-2015-052783. doi: 10.1136/tobaccocontrol-2015-052783.
18	CDC 2011	Centers for Disease Control and Prevention (CDC). Tobacco-related mortality. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality . (Accessed 9/12/2011).
19	CDC MMWR, CDC's Vision for Public Health Surveillance in the 21st Century, 2012	Centers for Disease Control and Prevention. July 27, 2012. CDC's Vision for Public Health Surveillance in the 21st Century. MMWR Supplement Vol. 61.
20	CDC SAMMEC 2011	CDC SAMMEC: Centers for Disease Control and Prevention. 2011. Smoking Attributable Mortality, Morbidity, and Economic Costs.
21	Chang et al. 2016	Chang CM, Edwards SH, Arab A, Del Valle-Pinero A, Yang L, and Hatsukami DK. 2016. Biomarkers of Tobacco Exposure: Summary of an FDA-sponsored Public Workshop. <i>Cancer Epidemiol Biomarkers Prev.</i> 26(3):1-12.
22	Choi et al. 2012	Choi K, Fabian L, Mottey N, Corbett A, and Forster J. 2012. Young adults' favorable perceptions of snus, dissolvable tobacco products, and electronic cigarettes: Findings from a focus group study. <i>Am J Public Health.</i> 102(11):2088-2093.
23	Cobb et al. 2010	Cobb CO, Weaver MF, Eissenberg T. 2010. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. <i>Tob Control.</i> Oct;19(5):367-73.
24	Coggins 1998	Christopher R. E. Coggins. 1998. A Review of Chronic Inhalation Studies with Mainstream Cigarette Smoke in Rats and Mice. <i>Toxicologic Pathology.</i> Vol. 26. No. 3, pp. 307-1 14.
25	Coggins 2007	Christopher R. E. Coggins. 2007. An Updated Review of Inhalation Studies with Cigarette Smoke in Laboratory Animals. <i>International Journal of Toxicology,</i> 26:331-338.
26	Davis et al. 2006	Davis TC, Wolf MS, Bass PF, Middlebrooks M, Kennen E, Baker DW, Bennett CL, Durazo-Arvizu R, Bocchini A, Savory S, and Parker RM. 2006. Low literacy impairs comprehension of prescription drug warning labels. <i>J Gen Intern Med.</i> 21:847-851. (Accessed June 6, 2016 at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831578/pdf/jgi0021-0847.pdf)
27	Djordjevic et al. 1993	Djordjevic MV, Brunnemann KD, and Hoffmann D. 1993. The need for regulation of carcinogenic N-Nitrosamines on oral snuff. <i>Fd Chem Toxic</i> 31(7), 497-501.
28	Doll and Hill 1952	Doll R and Hill A. Study of the Aetiology of Carcinoma of the Lung. <i>Br Med J.</i> 1952 Dec 13; 2(4797): 1271-1286.

No.	Citation	Title
29	Farrell and Petersen 2010	Farrell D, and Petersen JC. 2010. The growth of internet research methods and the reluctant sociologist. <i>Sociological Inquiry</i> . 80(1):114-125.
30	FDA 2014	FDA 2014. Letter to R.J. Reynolds Tobacco Company containing official minutes of May 29, 2014 meeting.
31	FDA Briefing Document for 4-9-2015 SMNA TPSAC meeting	FDA Briefing Document: April 9 -10, 2015 Meeting of the Tobacco Products Scientific Advisory Committee. Modified Risk Tobacco Product Applications for ten General brand snus tobacco products (FDA Submission Tracking Numbers MR0000020-MR0000029) Swedish Match North America, Inc.
32	FDA MRTPA Draft Guidance 2012	Guidance for Industry. Modified Risk Tobacco Product Applications. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products. March 2012.
33	FDA Safety Reporting Portal for Tobacco Products 2016	FDA Safety Reporting Portal for Tobacco Products. https://www.safetyreporting.hhs.gov
34	77 Fed. Reg. 200034 (April 3, 2012)	Department of Health and Human Services- Food and Drug Administration [Docket No. FDA-2012-D-0049]. Draft Guidance for Industry: Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under the Federal Food, Drug, and Cosmetic Act.
35	Fix et al. 2017	Brian V Fix, Sarah E Adkison, Richard J O'Connor, Maansi Bansal-Travers, K Michael Cummings, Vaughan W Rees, Dorothy K Hatsukami. 2017. Evaluation of modified risk claim advertising formats for Camel Snus. <i>Health Education Journal</i> , Vol. 76(8) 971-985.
36	Fong et al. 2016	Fong G, Elton-Marshall T, Driezen P, Kaufman A, Cummings KM, Choi K, Kwan J, et al. 2016. Adult perceptions of the harmfulness of tobacco products: Descriptive findings from wave 1 of the PATH study, 2013-14. Poster session presented at: 2016 Society for Research on Nicotine and Tobacco Annual Meeting; 2016 March 2-5; Chicago, IL.
37	Foulds & Ramström, 2006	Foulds J and Ramstrom L. 2006. Causal Effects of Smokeless Tobacco on Mortality in CPS-I and CPS-II? <i>Cancer Causes and Control</i> 17: 227-228.
38	Friedman et al. 1997	Friedman GD, Tekawa I, Sadler M, and Sidney S. 1997. Smoking and mortality: The Kaiser Permanente experience. In: Shopland DR, Burns DM, Garfinkel L, Samet J, editors. Changes in Cigarette Related Disease Risks and Their Implication for Prevention and Control. Smoking and Tobacco Control Monograph 8. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 477-499. NIH Publication No. 97-4213. (Accessed August 29, 2016 at http://cancercontrol.cancer.gov/brp/tcrb/monographs/8/m8_6.pdf)
39	Frost-Pineda et al. 2010	Frost-Pineda K, Appleton S, Fisher M, Fox K, and Gaworski CL. 2010. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction? <i>Nicotine Tob Res</i> . 12(11), 1055-1067.
40	Frost-Pineda et al. 2011	Frost-Pineda K, Liang Q, Liu J, Rimmer L, Jin Y, Feng S, Kapur S, Mendes P, Roethig H, Sarkar M. 2011. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. <i>Nicotine Tob Res</i> . Mar;13(3):182-93.

No.	Citation	Title
41	Glover et al. 1981	Glover ED, Christen AG, Henderson AH, Garrison W, Namath J, Hunter C, Fisk C, Seaver T, Campbell E, Houk R, Mercer B, Bradshaw T, Brett G, Lyle S, and Daniels C. 1981. Just a pinch between the cheek and gum. <i>J Sch Health</i> 51(6), 415-418.
42	Greer and Poulson 1983	Greer RO and Poulson TC. 1983. Oral tissue alterations associated with the use of smokeless tobacco by teen-agers. Part 1. Clinical findings. <i>Oral Surg</i> 56(3):275-284.
43	Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance 1996	Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance. ICH. April 1996.
44	Harris Interactive 2013	Harris Interactive. Americans less likely to say 18 of 19 industries are honest and trustworthy this year. December 12, 2013. The Harris Poll #96. (Accessed June 7, 2016 at http://media.theharrispoll.com/documents/Harris_Poll_96_-_2013_Industry_Regulation_12.12.2013.pdf)
45	Hatsukami et al. 1988	Hatsukami DK, Keenan RM, and Anton DJ. 1988. Topographical features of smokeless tobacco use. <i>Psychopharmacology</i> 96, 428-429.
46	Hatsukami et al. 1991	Hatsukami DK, Anton D, Callies A, and Keenan R. 1991. Situational factors and patterns associated with smokeless tobacco use. <i>J Beh Med</i> 14(4), 383-396.
47	Hatsukami et al. 2007	Hatsukami DK, Ebbert JO, Feuer RM, Stepanov I, Hecht SS. 2007. Changing smokeless tobacco products new tobacco-delivery systems. <i>Am J Prev Med.</i> 33(6 Suppl), S368-78.
48	Hatsukami et al. 2009	Hatsukami DK, Hanson K, Briggs A, Parascandola M, Genkinger JM, O'Connor R, Shields PG. 2009. Clinical trials methods for evaluation of potential reduced exposure products. <i>Cancer Epidemiol Biomarkers Prev.</i> 18(12), 3143-95.
49	Hatsukami et al. 2015	Hatsukami DK, Stepanov I, Severson H, Jensen JA, Lindgren BR, Horn K, Khariwala SS, Martin J, Carmella SG, Murphy SE, Hecht SS. 2015. Evidence supporting product standards for carcinogens in smokeless tobacco products. <i>Cancer Prev Res (Phila).</i> Jan;8(1):20-26.
50	Hatsukami et al. 2016	Hatsukami DK, Severson H, Anderson A, Vogel RI, Jensen J, Broadbent B, Murphy SE et al. 2016. Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. <i>Tob Control</i> 25:267-274.
51	Hatsukami et al. 2017	Hatsukami et al. Reduced nicotine content cigarettes and use of alternative nicotine products: Exploratory Trial. <i>Addiction.</i> 2017 January ; 112(1): 156-167.
52	Hecht 2005	Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. 2005. <i>Carcinogenesis</i> Vol.26 No.9 pp.1488-1492.
53	Hecht et al. 1975	Hecht SS, Ornaf RM, and Hoffmann D. 1975. Chemical studies on tobacco smoke. XXXIII. N'-nitrosornicotine in tobacco: analysis of possible contributing factors and biologic implications. <i>JNCI</i> 54:1237-1244.
54	Hecht et al. 2011	Hecht SS, Stepanov I, Hatsukami DK. 2011. Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. <i>Tob Control.</i> Nov;20(6):443.
55	Hecht et al. 2015	Hecht SS, Stepanov I, Carmella SG. 2015. Exposure and Metabolic Activation Biomarkers of Carcinogenic Tobacco-Specific Nitrosamines. <i>Acc Chem Res.</i> Dec 17. [Epub ahead of print].

No.	Citation	Title
56	Henley et al. 2005	Henley SJ, Thun MJ, Connell C, and Calle EE. 2005. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). <i>Cancer Causes Control</i> 16, 347-358.
57	Henley et al. 2007	Henley SJ, Connell CJ, Richter P, Husten C, Pechacek T, Calle EE and Thun MJ. 2007. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. <i>Tobacco Control</i> 16:22-28.
58	Henningfield et al. 2017	Henningfield JE, Fant RV, and Kleykamp BA. 2017. An Assessment of Camel Snus Abuse Liability.
59	Hoffmann et al. 1986	Hoffmann D, Harley NH, Fisenne I, Adams JD, and Brunnemann KD. 1986. Carcinogenic agents in snuff. <i>JNCI</i> 76, 435-437.
60	Hoffmann et al. 1987	Hoffmann D, Adams JD, Lisk D, Fisenne I, and Brunnemann KD. 1987. Toxic and carcinogenic agents in dry and moist snuff. <i>JNCI</i> 79, 1281-1286.
61	IARC 1985	IARC: International Agency for Research on Cancer. 1985. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Tobacco Habits Other than Smoking; Betel-quid and Areca-Nut Chewing; and Some Related Nitrosamines. 37, International Agency for Research on Cancer, Lyon, France. (http://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Evaluation-Of-Carcinogenic-Risks-To-Humans/Tobacco-Habits-Other-Than-Smoking-Betel-Quid-And-Areca-Nut-Chewing-And-Some-Related-Nitrosamines-1985)
62	IOM 2004	Institute of Medicine. Health Literacy: A Prescription to End Confusion. 2004. Institute of Medicine. Washington DC: The National Academies Press. (https://www.ncbi.nlm.nih.gov/books/NBK216032/)
63	IOM 2012	IOM (Institute of Medicine). 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. (https://www.nap.edu/read/13294/chapter/1#xv)
64	Johnson et al. 2009	Michael D. Johnson, Jodi Schilz, Mirjana V. Djordjevic, Jerry R. Rice, and Peter G. Shields. 2009. Evaluation of In vitro Assays for Assessing the Toxicity of Cigarette Smoke and Smokeless Tobacco. <i>Cancer Epidemiol Biomarkers Prev.</i> 18(12).
65	Kabat et al. 1994	Kabat G C: (Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA), Chang C J and Wynder EL. 1994. The role of tobacco, alcohol use and body mass index in oral and pharyngeal cancer. <i>International Journal of Epidemiology</i> ; 23: 1137-1144.
66	Kaufman et al. 2014	Kaufman AR, Mays D, Koblitz AR, and Portnoy DB. 2014. Judgments, awareness, and the use of snus among adults in the United States. <i>Nicotine Tob Res.</i> 16(10):1404-1408.
67	Kiviniemi and Kozlowski 2015	Kiviniemi MT and Kozlowski LT. 2015. Deficiencies in public understanding about tobacco harm reduction: Results from a United States national survey. <i>Harm Reduct J.</i> 12:21. (Accessed June 6, 2016 at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487951/pdf/12954_2015_Article_55.pdf)
68	Kotlyar et al. 2011	Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I, Murphy SE, Hecht SS, and Hatsukami DK. 2011. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. <i>Cancer Epidemiol Biomarkers Prev.</i> 20(1), 91-100.

No.	Citation	Title
69	Kozlowski and Sweanor 2016	Kozlowski LT and Swseanor D. 2016. Withholding differential risk information on legal consumer nicotine/tobacco products: The public health ethics of health information quarantines. <i>Int J Drug Policy</i> 32:17-23.
70	Kozlowski et al. 2003	Kozlowski LT, O'Connor RJ, Edwards BQ, and Flaherty BP. 2003. Most smokeless tobacco use is not a causal gateway to cigarettes: Using order of product use to evaluate causation in a national us sample. <i>Addiction</i> . 98(8):1077-1085.
71	Krautter et al. 2015	Krautter GR, Chen PX, and Borgerding MF. 2015. Consumption patterns and biomarkers of exposure in cigarette smokers switched to snus, various dissolvable tobacco products, dual use, or tobacco abstinence. <i>Regulatory Toxicology and Pharmacology</i> 71(2), 186-197.
72	Kutner et al. 2006	Kutner M, Greenberg E, Jin Y, and Paulsen C. 2006. The Health Literacy of America's Adults: Results from the 2003 National Assessment of Adult Literacy. U.S. Department of Education. Washington, DC: National Center for Education Statistics. (Accessed May 6, 2016 at https://nces.ed.gov/pubs2006/2006483.pdf)
73	Langan 2015	Langan H. September 29, 2015. New study: Traditional marketing fails to gain consumer trust. (Accessed June 13, 2016 at https://www.expertcity.com/blog/2015/09/29/new-study-traditional-marketing-fails-to-gain-consumer-trust/)
74	Lawler et al. 2013	Tameka S. Lawler, Stephen B. Stanfill, Liqin Zhang, David L. Ashley, Clifford H. Watson. 2013. Chemical characterization of domestic oral tobacco products: Total nicotine, pH, unprotonated nicotine and tobacco-specific N-nitrosamines. <i>Food and Chemical Toxicology</i> 57:380–386.
75	Lee 2014	Lee PN. 2014. Health risks related to dual use of cigarettes and snus -- a systematic review. <i>Regulatory Toxicology and Pharmacology</i> 69:125-134.
76	Lee 2015	Lee PN. 2015. Appropriate and inappropriate methods for investigating the gateway hypothesis, with a review of the evidence linking prior snus use to later cigarette smoking. <i>Harm Reduct J</i> . 12:8. (Accessed June 13, 2016 at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369866/pdf/12954_2015_Article_40.pdf)
77	Lee and Hamling 2009a	Lee PN and Hamling J. 2009a. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. <i>BMC Medicine</i> 7:36 doi10.1186/1741-7015-7-36.
78	Lemmonds et al. 2005	Lemmonds CA, Hecht SS, Jensen JA, Murphy SE, Carmella SG, Zhang Y, and Hatsukami DK. 2005. Smokeless tobacco topography and toxin exposure. <i>Nic & Tob Res</i> 7(3), 469-474.
79	Levy et al. 2004	Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, and Warner KE. 2004. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. <i>Cancer Epidemiol Biomarkers Prev</i> . 13(12), 2035-2042.
80	Lewin et al. 1998	Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biörklund A, and Rutqvist LE. 1998. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. <i>Cancer</i> . 82(7):1367-1375.

No.	Citation	Title
81	Liu et al. 2015	Liu ST, Nemeth JM, Klein EG, Ferketich AK, Kwan MP, and Wewers ME. 2015. Risk perceptions of smokeless tobacco among adolescent and adult users and nonusers. <i>J Health Comm.</i> 20:599-606.
82	Lundqvist et al. 2009	Lundqvist G, Sandstrom H, Ohman A, and Weinehall L. 2009. Patterns of tobacco use: A 10-year follow-up study of smoking and Snus habits in a middle-aged Swedish population. <i>Scandinavian J Public Health</i> 37:161-167.
83	Luo et al. 2007	Luo J, Ye W, Zendejdel K, Adami J, Adami HO, Boffetta P, and Nyrén O. 2007. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. <i>Lancet.</i> 369(9578), 2015-2020.
84	Mashberg et al. 1993	Mashberg A, Boffetta P, Winkelman R, and Garfinkel L. 1993. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. <i>Cancer</i> 72(4), 1369-1375.
85	McAdam et al. 2013	McAdam KG, Faizi A, Kimpton H, Porter A, and Rodu B. 2013. Polycyclic aromatic hydrocarbons in US and Swedish smokeless tobacco products. <i>Chemistry Central J</i> 7, 1-18.
86	McAdam et al. 2015b	McAdam K, Kimpton H, Vas C, Rushforth D, Porter A, Rodu B. 2015. The acrylamide content of smokeless tobacco products. <i>Chem Cent J.</i> Oct 12;9:56.
87	Messer et al. 2007	Messer K, Pierce JP, Zhu SH, Hartman AM, Al-Delaimy WK, Trinidad DR, and Gilpin EA. 2007. The California tobacco control program's effect on adult smokers: (1) Smoking cessation. <i>Tob Control</i> 16:85-90.
88	Moldoveanu and Gerardi 2011	Moldoveanu SC, Gerardi AR. 2011. Acrylamide analysis in tobacco, alternative tobacco products, and cigarette smoke. <i>Journal of Chromatographic Science</i> Mar;49(3): 234-242.
89	Niaura 2016	Niaura R. 2016. Re-thinking nicotine and its effects. Schroeder Institute for Tobacco Research and Policy Studies.
90	Nordskog et al. 2015	Nordskog BK, Brown BG, Marano KM, Campell LR, Jones BA, Borgerding MF. 2015. Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. <i>Inhal Toxicol.</i> Mar 19:1-10. [Epub ahead of print]
91	NTBM Methodological Report 2016	National Tobacco Behavior Monitor Methodological Report, October 2016.
92	Nutt et al. 2014	Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Milton A, Polosa R, Ramsey J, and Sweanor D. 2014. Estimating the harms of nicotine-containing products using the MCDA approach. <i>Eur Addict Res</i> 20:218-225.
93	O'Connor et al. 2007	O'Connor RJ, McNeill A, Borland R, Hammond D, King B, Boudreau C, and Cummings KM. 2007. Smokers' beliefs about the relative safety of other tobacco products: Findings from the ITC Collaboration. <i>Nicotine Tob Res.</i> 9(10):1033-1042.
94	Österdahl et al. 2004	Österdahl B-G, Jansson C, and Paccou A. 2004. Decreased levels of tobacco-specific N-Nitrosamines in moist snuff on the Swedish market. <i>J Agric Food Chem</i> 52:5085-5088.

No.	Citation	Title
95	Pankow et al. 2007	James F. Pankow, Karen H. Watanabe, Patricia L. Toccalino, Wentai Luo, and Donald F. Austin. 2007. Calculated Cancer Risks for Conventional and 'Potentially Reduced Exposure Product Cigarettes. <i>Cancer Epidemiol Biomarkers Prev</i> ;16(3):584-92.
96	Patel et al. 2016	Patel MI, Wang A, Kapphahn K, Desai M, Chlebowski TW, Simon MS, Bird CE, Corbie-Smith G, Gomez SL, Adams-Campbell LL, Cote ML, Stefanick ML and Wakelee HA. 2016. Racial and ethnic variations in lung cancer incidence and mortality: results from the women's health initiative. <i>J Clin Oncol</i> 34(4):360-368.
97	Pepper et al. 2015	Pepper JK, Emery SL, Ribisi KM, Rini CM, and Brewer NT. 2015. How risky is it to use e-cigarettes? Smokers' beliefs about their health risks form using novel and traditional tobacco products. <i>J Behav Med.</i> 38(2):318-326.
98	Perrin and Duggan 2015	Perrin A, and Duggan M. 2015. Americans' Internet Access: 2000-2015. Pew Research Center, June 2015.
99	Perry et al. 1993	Gross AJ, Lackland DT, Tu DS. 1995. Oral cancer and smokeless tobacco: Literature review and meta-analysis. <i>Environment International</i> , Vol. 21, No. 4, pp 381-394. (N.B. Briefing Book reference Perry et al. 1993 @ pg. 30 should be Gross et al. 1995)
100	Perry 2018	Perry CL, Perez A, Bluestein M, Garza N, Obinwa U, Jackson C, Clendennen SL, Loukas A, Harrell MB. Youth or Young Adults: Which Group Is at Highest Risk for Tobacco Use Onset? <i>Journal of Adolescent Health</i> 00:1-8.
101	Piano, 2010	Piano MR, Benowitz NL, FitzGerald GA, Corbridge S, Heath J, Hahn E, Pechacek TF, Howard G; on behalf of the American Heart Association Council on Cardiovascular Nursing. 2010. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. <i>Circulation.</i> 122:1520-1544.
102	Pierce et al. 1996	Pierce JP, Choi W, Gilpin EA, Farkas AJ, and Merritt RK. 1996. Validation of susceptibility as a predictor of which adolescents take up smoking in the United States. <i>Health Psychol.</i> 15(5):355-361.
103	Ramboll Environ 2016	Ramboll Environ 2016. A systematic, critical review of the literature pertaining to the risks of oral and lung cancers, cardiovascular disease and respiratory diseases among snus and smokeless tobacco users.
104	Raymond et al. 2002	Raymond EG, Dalebout SM, and Camp SI. 2002. Comprehension of a prototype over-the-counter label for an emergency contraceptive pill product. <i>Obstet Gynecol.</i> 100:342-349. (Accessed June 6, 2016 at http://journals.lww.com/greenjournal/Fulltext/2002/08000/Comprehension_of_a_Prototype_Over_the_Counter.24.aspx#)
105	Regan et al. 2012	Regan AK, Dube SR, and Arrazola R. 2012. Smokeless and flavored tobacco products in the U.S. 2009 Styles Survey results. <i>Am J Prev Med.</i> 42(1):29-36.
106	Richardson et al. 2014	Richardson A, Pearson J, Xiao H, Stalgaitis C, and Vallone D. 2014. Prevalence, harm perceptions, and reasons for using noncombustible tobacco products among current and former smokers. <i>Am J Public Health.</i> 104(8):1437-1444.
107	Rickert et al. 2009	Rickert WS, Joza PJ, Trivedi AH, Momin RA, Wagstaff WG, and Lauterbach JH. 2009. Chemical and toxicological characterization of commercial smokeless tobacco products available on the Canadian market. <i>Regulatory Toxicology and Pharmacology</i> 53:121-133.

No.	Citation	Title
108	Rock and Kono 2008	Rock K and Kono H. The Inflammatory Response to Cell Death. <i>Annu Rev Pathol.</i> 2008; 3: 99–126.
109	Rodu and Jansson 2004	Rodu B and Jansson C. 2004. Smokeless tobacco and oral cancer: a review of the risks and determinants. <i>Crit Rev. Oral Biol. Med.</i> 15, 252-263.
110	Roosaar et al. 2008	Roosaar A, Johansson AL, Sandborgh-Englund G, Axéll T, and Nyrén O. 2008. Cancer and mortality among users and nonusers of snus. <i>Int J Cancer.</i> 123(1), 168-173.
111	Rosenquist et al. 2005	Rosenquist K, Wennerberg J, Schildt EB, Bladström A, Hansson BG, and Andersson G. 2005. Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. <i>Acta Otolaryngol.</i> 125(9), 991-998.
112	Round et al. 2015	Round EK, Campbell LR, Stiles MF, Dixon M, Borgerding MF. 2015. Changes in biomarkers of exposure and subjective effects when smokers switch to dual use of cigarettes and either snus or a dissolvable tobacco product: a summary of three clinical studies. <i>Beiträge zur Tabakforschung International</i> 26(6): 242-260.
113	Rudd 2007	Rudd RE. Health literacy skills of U.S. adults. 2007. <i>Am J Health Behav.</i> 31(Suppl 1):S8-S18.
114	Rutqvist et al. 2011	Rutqvist LE, Curvall M, Hassler T, Ringberger T, and Wahlberg I. 2011. Swedish snus and the GothiaTek™ standard. <i>Harm Reduction J</i> 8:1-9.
115	SAMHSA 2010a	SAMHSA. NSDUH 2010. Table 4.3B: Past Year Initiation of Cigarette Use among Persons Aged 12 or Older, Persons Aged 12 or Older at Risk for Initiation of Cigarette Use, and Past Year Cigarette Users Aged 12 or Older, by Demographic Characteristics: Numbers in Thousands and Percentages. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2009 and 2010.
116	SAMHSA 2010b	SAMHSA. Recent Smoking Cessation. Rockville, MD: Substance Abuse and Mental Health Services Administration, April 8, 2010.
117	Schildt et al. 1998	Schildt EB, Eriksson M, Hardell L, and Magnuson A. 1998. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. <i>Int. J. Cancer</i> 77, 341-346.
118	Schmidt et al. 2016	Schmidt AM, Ranney LM, Pepper JK, and Goldstein AO. 2016. Source credibility in tobacco control messaging. <i>Tob Reg Science.</i> 2(1):31-37.
119	Schwartz et al. 1998	Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA. 1998. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. <i>J Natl Cancer Inst.</i> Nov 4;90(21):1626-36.
120	Shiffman et al. 2011	Shiffman S, Gerlach KK, Sembower MA, and Rohay JM. 2011. Consumer understanding of prescription drug information: An illustration using an antidepressant medication. <i>Ann Pharmacother.</i> 45(4):452-458.

No.	Citation	Title
121	SMNA MRTPA TPL Review	Swedish Match North America, Inc. Modified Risk Tobacco Product (MRTP) Application -- Technical Project Lead (TPL) Review, Swedish Match submission date June 10, 2014.
122	Song et al. 2016	M.-A. Song et al. 2016. Chemical and toxicological characteristics of conventional and low-TSNA moist snuff tobacco products. <i>Toxicology Letters</i> 245:68–77.
123	Stepanov et al. 2008	Stepanov I, Jensen J, Hatsukami D, and Hecht SS. 2008. New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levels. <i>Nic & Tob Res</i> 10(12), 1773-1782.
124	Stepanov et al. 2010	Stepanov I, Villalta PW, Knezevich A, Jensen J, Hatsukami D, and Hecht SS. 2010. Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography – mass spectrometry. <i>Chem Res Toxicol</i> 23, 66-73.
125	Stepanov et al. 2012	Stepanov I, Biener L, Knezevich A, Nyman AL, Bliss R, Jensen J, Hecht SS, Hatsukami DK. 2012. Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: Findings from Round 1 of the New Product Watch. <i>Nicotine Tob Res</i> . Mar;14(3):274-281.
126	Stepanov et al. 2013	Stepanov I, Yershova K, Carmella S, Upadhyaya P, Hecht SS. 2013. Levels of (S)-N'-nitrosornicotine in U.S. tobacco products. <i>Nicotine Tob Res</i> . Jul;15(7):1305-1310.
127	Stepanov et al. 2014	Stepanov I, Biener L, Yershova K, Nyman AL, Bliss R, Parascandola M, Hatsukami DK. 2014. Monitoring tobacco-specific N-nitrosamines and nicotine in Novel smokeless tobacco products: Findings from Round II of the New Product Watch. <i>Nicotine Tob Res</i> . Aug;16(8):1070-1078.
128	Sterling et al. 1992	Sterling TD, Rosenbaum WL, Weinkam JJ. 1992. Analysis of the relationship between smokeless tobacco and cancer based on data from the National Mortality Followback Survey. <i>J Cl. Epidemiol Vol.</i> 45, No. 3, pp. 223-231.
129	Stockwell et al. 1986	Stockwell HG, Lyman GH. 1986. Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. <i>Head Neck Surg</i> . Nov-Dec;9(2):104-10.
130	SAMHSA 1999	Substance Abuse and Mental Health Services Administration. 1999. National Household Survey on Drug Abuse. Substance Abuse and Mental Health Statistics. U.S. Department of Health & Human Services, Office of Applied Studies. Washington, DC. (Accessed August 29, 2016 at http://www.icpsr.umich.edu/icpsrweb/NAHDAP/studies/3239)
131	TCA	U.S. FDA. Family Smoking Prevention and Tobacco Control Act, Public Law 111-31- June 22, 2009.
132	Theophilus et al. 2015	Theophilus EH, Hayes JR, Ayres PH, Morgan WT, Potts RJ, Garner CD, Fallacara DM, Hejtmancik MR, and Singer AW. 2015. Toxicological evaluation of smokeless tobacco: 2-year chronic toxicity and carcinogenicity feeding study in Wistar Han rats. <i>Experimental and Toxicologic Pathology</i> 67: 539-550.
133	Thun et al. 2000	Thun MJ, Apicella LF, and Henley SJ. 2000. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. <i>JAMA</i> 284, 706-712.

No.	Citation	Title
134	USDHHS 1989	USDHHS: U.S. Department of Health and Human Services. 1989. Reducing the Health Consequences of Smoking: A Report of the Surgeon General. Rockville, MD. Public Health Service, DHHS Publication No. (CDC) 89-8411. (https://profiles.nlm.nih.gov/NN/B/B/X/S/)
135	USDHHS 1998	USDHHS: U.S. Department of Health and Human Services. 1998. Tobacco Use Among U.S. Radical/Ethnic Minority Groups—African Americans, American Indians and Alaska Native, Asian Americans and Pacific Islanders, and Hispanics. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (https://www.cdc.gov/tobacco/data_statistics/sgr/1998/index.htm)
136	USDHHS 2010 (SGR 2010)	USDHHS: U.S. Department of Health and Human Services. 2010. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention. (https://www.ncbi.nlm.nih.gov/books/NBK53017/)
137	USDHHS 2012 (SGR 2012)	U.S. Department of Health and Human Services. 2012. Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (https://www.surgeongeneral.gov/library/reports/preventing-youth-tobacco-use/index.html)
138	USDHHS 2014	USDHHS: U.S. Department of Health and Human Services. 2014. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (https://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html#fullreport)
139	USNCHS 2000	U.S. National Center for Health Statistics. 2000. Vital Statistics of the United States, U.S. Death and Death Rates, by Age and Leading Cause, Available at: http://www.allcountries.org/uscensus/129_death_and_death_rates_by_age.html
140	Wackowski and Delnevo 2016	Wackowski OA, and Delnevo CD. 2016. Young adults' risk perceptions of various tobacco products relative to cigarettes: Results from the national young adult health survey. <i>Health Educ Behav.</i> 43(3):328-336.
141	Weiss et al. 2005	Weiss BD, Mays MZ, Martz W, Castro KM, DeWalt DA, Pignone MP, Mockbee J, and Hale FA. 2005. Quick assessment of literacy in primary care: The Newest Vital Sign. <i>Ann Fam Med.</i> 3(6):514-522. (Accessed April 28, 2016 at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1466931/pdf/0030514.pdf)
142	Williams and Horm 1977	Williams RR and Horm JW. 1977. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. <i>J. Natl. Cancer Inst.</i> 58, 525-547.
143	Winn et al. 1981	Winn DM, Blot WJ, Shy CM, Pickle LW, Toledo A, and Fraumeni JF Jr. 1981. Snuff dipping and oral cancer among women in the southern United States. <i>N Engl J Med.</i> 304(13), 745-749.

No.	Citation	Title
144	Wolf et al. 2006	Wolf MS, Davis TC, Tilson HH, Bass PF, and Parker RM. 2006. Misunderstanding of prescription drug warning labels among patients with low literacy. <i>Am J Health-Syst Pharm.</i> 63:1048-1055.
145	World Health Organization, Public health surveillance, 2012	World Health Organization. Public health surveillance. http://www.who.int/topics/public_health_surveillance/en/
146	Wynder and Stellman 1977	Wynder E and Stellman S. 1977. Comparative Epidemiology of Tobacco-Related Cancer. <i>Cancer Research</i> 37, 4608-4622.
147	Yuan et al. 2011a	Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, Moy KA, Davis AB, Tao L, Chen M, Han S, Nelson HH, Yu MC, and Hecht SS. 2011. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. <i>Cancer Res</i> 71(21), 6749-57.
148	Yuan et al. 2014	Yuan J-M, Butler JM, Stepanov I, and Hecht SS. 2014. Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer. <i>Cancer Res</i> 74(2):401-411.
149	Zeller et al. 2009	Zeller M, Hatsukami D, Strategic Dialogue on Tobacco Harm Reduction Group., Backinger CL, Benowitz NL, Biener L, Burns DM, Clark P, Connolly G, Djordjevic M, Eissenberg T, Giovino G, Healton CG, Hecht S, Husten C, Kobus K, Leischow S, Levy DT, Marcus S, Myers M, Parascandola M, Pongshe P, Shields P, Slovic P, Swenor D, and Warner KE. 2009. The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the U.S. <i>Tob. Control</i> 18, 324-332.